SWOG clinical trial number
SWOG-9347 (INT-0142) (E3193)

Phase III Comparison of Tamoxifen versus Tamoxifen with Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer < 3 cm, Intergroup

Closed
Phase
Published
Abbreviated Title
Phase III Comparison of Tamoxifen versus Tamoxifen with Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer < 3 cm, Intergroup
Activated
10/15/1994
Closed
11/06/1997

Publication Information Expand/Collapse

2014

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group

AJ Tevaarwerk;M Wang;F Zhao;J Fetting;D Cella;LI Wagner;S Martino;JN Ingle;J Sparano;L Solin;WC Wood;NJ Robert Journal of Clinical Oncology Dec 10;32(35):3948-3958

2004

Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study

LL Hughes;RJ Gray;LJ Solin;S Martino;D Tripathy;JN Ingle;WC Wood Cancer 101(5):969-972

2003

Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer < 3 cm

NJ Robert;M Wang;D Cella;S Martino;D Tripathy;J Ingle;LJ Solin;WC Wood Proc of the American Society of Clinical Oncology 22:5(#16)